Estimated Study Completion Date. The WISDOM Study compares the routine annual mammogram schedule to a personalized screening schedule based on a womans individual risk factors.
The Wisdom Study On Twitter Women Who Join Wisdom Will Help Advance The Science Of Breast Cancer Screenings Making It Better For All Women Join Now Https T Co Io1rotj9sy Womenshealth Wisdom Science Endtheconfusion Breastcancerawareness
Women receive mixed messages about what type of breast cancer screening they should have and how often they should have mammograms.
Wisdom breast cancer study. The multicenter trial will enroll 100000 women powered for a primary endpoint of non-inferiority with respect to the number of late stage cancers detected. The WISDOM Study Women Informed to Screen Depending On Measures of risk is a pragmatic adaptive randomized clinical trial comparing a comprehensive risk-based or personalized approach to traditional annual breast cancer screening. Any woman between the ages of 40 and 74 who has never had breast cancer can participate.
The Wisdom Studys goal is to determine if more a personalized approach to breast cancer screening leads to better outcomes and less confusion. It is the first study conducted through Athena Breast Health Network a collaboration of the five University of California medical centers to drive innovation in breast cancer prevention screening and treatment. Estimated Primary Completion Date.
The WISDOM Study uses randomization to assign participants to one group or the other. There is a small chance we will find that you have inherited a variation in a gene like the BRCA1 and BRCA2 genes that is known to be related to breast cancer risk. Who Can Join the WISDOM Study.
Like the flip of a coin when you are randomized a computer determines which group you will be in. The project called the WISDOM study will be led by breast cancer researcher Laura Esserman MD MBA professor of surgery and director of the Carol Franc Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center. This method is used in research because it is the best way to test two options with the least amount of bias.
Sanford Health and five University of California medical centers teamed up as members of the Athena Breast Health Network for the study which began Nov. Breast cancer researcher Laura Esserman MD MBA consults with a patient at UCSF. The short study time in combination with design choices of not requiring study.
The study is designed to investigate whether women over 40 should get a routine mammogram every year or whether the frequency of mammography should be determined by. The Wisdom study is enrolling 100000 women in the age range of 40-74 years old. The Wisdom Study tests a personalized risk-based approach to breast cancer screening.
1 2017 and will last five years. The WISDOM study which began recruiting last year is seeking to bring on more than 100000 women to better understand the best approach for. Wisdom Breast Cancer Screening Study.
WISDOM Women Informed to Screen Depending on Measures of Risk is a randomized trial to assess whether personalized breast cancer screening-where women are screened biannually annually biennially or not at all depending on risk and age-can prevent as many advanced stage IIB or higher cancers as annual screening in women ages 40-74 years across 5 years of trial time. A Preference-Tolerant RCT of Personalized vs. The WISDOM Study hopes to transform breast cancer screening and create the most effective screening protocols for women in every stage of life.
They are looking at women with no history of breast cancer or DCIS ductal carcinoma in situ. Enabling a Paradigm Shift. Alexander Borowsky discusses the Wisdom Breast Cancer Study.
WISDOM is looking for women from 40 to 74 who live in the United States and have not had breast cancer. The WISDOM Study Women Informed to Screen Depending On Measures of risk is a pragmatic adaptive randomized clinical trial comparing a. This study is hoping to enroll 100000 California women age 40 and above to participate in a pragmatic preference tolerated randomized controlled trial design where a participant can choose to have an annual mammogram to have a personalized mammogram screen schedule based on their own risk or to be randomized into either arm of the study.
WISDOM is the result of a 5-year 141 million grant from the Patient-Centered Outcomes Research Institute PCORI. Annual Screening for Breast Cancer Wisdom Study Actual Study Start Date.
